[go: up one dir, main page]

BRPI0711889B8 - método para produção de sinvastatina, composição de matéria, método para fabricação de huvastatina, método para fabricação de sinvastatina, e método para fabricação de uma composição de matéria de sinvastatina ou huvastatina - Google Patents

método para produção de sinvastatina, composição de matéria, método para fabricação de huvastatina, método para fabricação de sinvastatina, e método para fabricação de uma composição de matéria de sinvastatina ou huvastatina

Info

Publication number
BRPI0711889B8
BRPI0711889B8 BRPI0711889A BRPI0711889A BRPI0711889B8 BR PI0711889 B8 BRPI0711889 B8 BR PI0711889B8 BR PI0711889 A BRPI0711889 A BR PI0711889A BR PI0711889 A BRPI0711889 A BR PI0711889A BR PI0711889 B8 BRPI0711889 B8 BR PI0711889B8
Authority
BR
Brazil
Prior art keywords
making
simvastatin
huvastatin
matter
composition
Prior art date
Application number
BRPI0711889A
Other languages
English (en)
Inventor
Xie Xinkai
Tang Yi
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BRPI0711889A2 publication Critical patent/BRPI0711889A2/pt
Publication of BRPI0711889B1 publication Critical patent/BRPI0711889B1/pt
Publication of BRPI0711889B8 publication Critical patent/BRPI0711889B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

método para produção de sinvastatina, composição de matéria, método para fabricação de huvastatina, método para fabricação de sinvastatina, e método para fabricação de uma composição de matéria de sinvastatina ou huvastatina a invenção aqui divulgada refere-se a métodos e materiais para produção de sinvastatina e compostos associados tal como huvastatina.
BRPI0711889A 2006-05-24 2007-05-24 método para produção de sinvastatina, composição de matéria, método para fabricação de huvastatina, método para fabricação de sinvastatina, e método para fabricação de uma composição de matéria de sinvastatina ou huvastatina BRPI0711889B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80808806P 2006-05-24 2006-05-24
US60/808.088 2006-05-24
PCT/US2007/012362 WO2007139871A2 (en) 2006-05-24 2007-05-24 Methods and materials for making simvastatin and related compounds

Publications (3)

Publication Number Publication Date
BRPI0711889A2 BRPI0711889A2 (pt) 2012-01-10
BRPI0711889B1 BRPI0711889B1 (pt) 2019-12-24
BRPI0711889B8 true BRPI0711889B8 (pt) 2021-05-25

Family

ID=38779209

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711889A BRPI0711889B8 (pt) 2006-05-24 2007-05-24 método para produção de sinvastatina, composição de matéria, método para fabricação de huvastatina, método para fabricação de sinvastatina, e método para fabricação de uma composição de matéria de sinvastatina ou huvastatina

Country Status (11)

Country Link
US (4) US8211664B2 (pt)
EP (1) EP2032715B1 (pt)
KR (1) KR101455794B1 (pt)
CN (1) CN101490271B (pt)
AT (1) ATE543910T1 (pt)
BR (1) BRPI0711889B8 (pt)
CA (1) CA2652883C (pt)
IL (1) IL195341A (pt)
MX (1) MX2008014778A (pt)
RU (1) RU2447152C2 (pt)
WO (1) WO2007139871A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101490271B (zh) 2006-05-24 2014-03-12 加利福尼亚大学董事会 制备辛伐他汀和相关化合物的方法和材料
WO2009056539A1 (en) * 2007-10-30 2009-05-07 Dsm Ip Assets B.V. Fermentative production of simvastatin
KR100959001B1 (ko) 2007-12-27 2010-05-20 선웨이 바이오테크 코., 엘티디. 알츠하이머병을 예방 및 치료하기 위한 조성물 및 그제조방법
ES2343049B1 (es) * 2008-10-15 2011-06-10 Neuron Biopharma, S.A. Biosintesis de derivados de monacolina j.
EP2483293B1 (en) 2009-09-30 2016-11-30 Codexis, Inc. Improved lov-d acyltransferase mediated acylation
WO2011044496A2 (en) 2009-10-08 2011-04-14 The Regents Of The University Of California LovD MUTANTS EXHIBITING IMPROVED PROPERTIES TOWARDS SIMVASTATIN SYNTHESIS
US9499803B2 (en) 2009-10-08 2016-11-22 The Regents Of The University Of California Variant LovD polypeptide
CN102043030A (zh) * 2009-10-22 2011-05-04 北京万全阳光医学技术有限公司 一种用高效液相色谱法测定烟酸辛伐他汀缓释片有关物质的方法
CN102010831B (zh) * 2010-05-26 2012-04-18 云南农业大学 一种产洛伐他汀紫色红曲菌霉mpt13
PL222067B1 (pl) * 2011-08-11 2016-06-30 Inst Biotechnologii I Antybiotyków Kaseta ekspresyjna, zastosowanie kasety ekspresyjnej, wektor ekspresyjny, komórka prokariotycznego gospodarza zawierająca wektor ekspresyjny, szczep bakteryjny oraz sposób wytwarzania polipeptydu
EP2730655A1 (de) 2012-11-12 2014-05-14 Evonik Industries AG Verfahren zur Umsetzung eines Carbonsäureesters unter Verwendung BioH-defizienter Zellen
CN104342417A (zh) * 2013-08-09 2015-02-11 南京朗恩生物科技有限公司 源于土曲霉的活性增强的酰基转移酶突变体
CN103772248B (zh) * 2014-01-06 2016-06-08 苏州汉酶生物技术有限公司 一种辛伐他汀侧链的酰基供体制备方法
CN103772247B (zh) * 2014-01-06 2016-06-08 苏州汉酶生物技术有限公司 一种可用于合成辛伐他汀铵盐的酰基供体的制备方法
CN103725727B (zh) * 2014-01-06 2016-06-08 苏州汉酶生物技术有限公司 一种辛伐他汀铵盐的制备方法
US20150315621A1 (en) * 2014-04-30 2015-11-05 The Regents Of The University Of California One-pot fermentation process for simvastatin production
KR101656235B1 (ko) * 2014-10-07 2016-09-12 대한민국 신규 스코풀라리옵시스 브레비카울리스 ｍ２４７９ 균주 및 이의 용도
CN105586325A (zh) * 2016-01-29 2016-05-18 重庆西南合成制药有限公司 一种洛伐他汀酰基转移酶突变体
CN108118042B (zh) * 2016-11-30 2021-01-15 中国科学院青岛生物能源与过程研究所 2-甲基丁酸侧链水解酶和产莫纳可林j的曲霉菌株及其构建方法与应用
EP3682022A4 (en) 2017-09-14 2021-06-09 Lifemine Therapeutics, Inc. HUMAN THERAPEUTIC TARGET MOLECULES AND MODULATORS THEREOF
CN109402086B (zh) * 2018-02-05 2020-08-11 中国科学院青岛生物能源与过程研究所 一种2-甲基丁酸侧链水解酶及其表达菌株和应用
WO2020018729A1 (en) * 2018-07-17 2020-01-23 Conagen Inc. Biosynthetic production of gamma-lactones
CN110857441B (zh) * 2018-08-24 2022-07-29 中国科学院青岛生物能源与过程研究所 一种产莫纳可林j的曲霉菌及其构建方法与应用
WO2020191385A1 (en) 2019-03-21 2020-09-24 Conagen Inc. Biosynthetic production of gamma- and delta-lactones using cytochrome p450 enzymes having subterminal hydroxylase activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391583B1 (en) 1998-12-18 2002-05-21 Wisconsin Alumni Research Foundation Method of producing antihypercholesterolemic agents
IL154068A0 (en) * 2000-07-27 2003-07-31 Teva Pharma Highly purified simvastatin compositions
AU2002337601A1 (en) 2001-07-25 2003-02-17 International Centre For Genetic Engineering And Biotechnology Process for the preparation of simvastatin
CN101490271B (zh) 2006-05-24 2014-03-12 加利福尼亚大学董事会 制备辛伐他汀和相关化合物的方法和材料
WO2007147801A1 (en) 2006-06-20 2007-12-27 Dsm Ip Assets B.V. Method for the production of simvastatin
WO2009077523A2 (en) 2007-12-18 2009-06-25 Dsm Ip Assets B.V. Improved statin production
EP2483293B1 (en) 2009-09-30 2016-11-30 Codexis, Inc. Improved lov-d acyltransferase mediated acylation

Also Published As

Publication number Publication date
US8211664B2 (en) 2012-07-03
EP2032715B1 (en) 2012-02-01
ATE543910T1 (de) 2012-02-15
RU2008151159A (ru) 2010-06-27
CA2652883C (en) 2016-01-05
EP2032715A2 (en) 2009-03-11
BRPI0711889A2 (pt) 2012-01-10
US20120315680A1 (en) 2012-12-13
US9970037B2 (en) 2018-05-15
BRPI0711889B1 (pt) 2019-12-24
WO2007139871A2 (en) 2007-12-06
CA2652883A1 (en) 2007-12-06
KR20090016488A (ko) 2009-02-13
MX2008014778A (es) 2009-01-28
US8951754B2 (en) 2015-02-10
WO2007139871A3 (en) 2008-12-24
US20090191602A1 (en) 2009-07-30
IL195341A0 (en) 2011-08-01
RU2447152C2 (ru) 2012-04-10
US10793884B2 (en) 2020-10-06
KR101455794B1 (ko) 2014-11-03
US20150203884A1 (en) 2015-07-23
CN101490271A (zh) 2009-07-22
CN101490271B (zh) 2014-03-12
EP2032715A4 (en) 2010-12-15
US20180355391A1 (en) 2018-12-13
IL195341A (en) 2017-01-31

Similar Documents

Publication Publication Date Title
BRPI0711889B8 (pt) método para produção de sinvastatina, composição de matéria, método para fabricação de huvastatina, método para fabricação de sinvastatina, e método para fabricação de uma composição de matéria de sinvastatina ou huvastatina
WO2008112939A3 (en) Composition and method for making oligo-benzamide compounds
DE602007012559D1 (de) H die schleimhaut
CU23774A3 (es) Inhibición de arni de expresión de alfa-enac
CL2008003038A1 (es) Compuestos derivados de pirrolidin-dionas espiroheterociclicas; proceso para la preparacion de dichos compuestos; composicion pesticida; metodo para combatir y controlar pestes; y compuestos intermediarios.
PL2207786T3 (pl) 2'-fluoro-2'-deoksy tetrahydrouryny jako inhibitory dezaminazy cytydyny
BRPI0908926A2 (pt) Compostos de policarbonato-poliorganosiloxano e/ou poliuretano-poliorganosiloxano
EA201001639A1 (ru) Композиции и способы их получения и применения
WO2008002674A3 (en) Bicyclic compositions and methods for modulating a kinase cascade
EA200970580A1 (ru) Таннат разагилина
BRPI0823506A8 (pt) composições e métodos para a produção de isoprene
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
MY150596A (en) Hsp90 inhibitors
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
CL2007003049A1 (es) Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
BRPI1008021A2 (pt) Método para fabricação de 2,6-dioxabiciclo-(3.3.0)-octano-4,8-diona
WO2008002676A3 (en) Biaryl compositions and methods for modulating a kinase cascade
TR201902386T4 (tr) Parçacıklı kalsiyum karbonat üretme metodu.
WO2009009041A3 (en) Compositions and methods for modulating a kinase cascade
BRPI0913105A2 (pt) composição de óleo de engrenagem, e, métodos para melhorar as propriedades de tração de uma composição de óleo de engrenagem e de um óleo de engrenagem
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
BRPI0817479A2 (pt) composição de óleo de engrenagem, e, método para melhorar as propriedade de tração de uma composição de óleo de engrenagem
ATE509931T1 (de) Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/12/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/05/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF